SciSparc Trial for Autism Gets Green Light
Ticker: SPRC · Form: 6-K · Filed: Dec 31, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Dec 31, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, regulatory-approval, biotech, autism
TL;DR
SciSparc's autism trial gets renewed approval from Israeli regulators, continuing its work on SCI-110.
AI Summary
On December 31, 2024, SciSparc Ltd. announced the renewal of approval from the Israeli Medical Cannabis Agency for its clinical trial focused on children with Autism Spectrum Disorder. This trial aims to evaluate the safety and efficacy of the Company's proprietary drug candidate, SCI-110, in treating this condition.
Why It Matters
This renewal allows SciSparc to continue its research into potential cannabis-based treatments for Autism Spectrum Disorder, a condition with significant unmet medical needs.
Risk Assessment
Risk Level: medium — Clinical trial renewals are positive but do not guarantee successful outcomes or regulatory approval for the drug itself.
Key Players & Entities
- SciSparc Ltd. (company) — The company issuing the press release and conducting the clinical trial.
- Israeli Medical Cannabis Agency (company) — The regulatory body that renewed the approval for the clinical trial.
- SCI-110 (drug_candidate) — SciSparc's proprietary drug candidate being tested in the clinical trial.
- Autism Spectrum Disorder (medical_condition) — The condition being studied in the clinical trial.
- December 31, 2024 (date) — The date the press release announcing the renewal was issued.
FAQ
What is the specific purpose of the renewed clinical trial for SciSparc?
The renewed clinical trial aims to evaluate the safety and efficacy of SciSparc's proprietary drug candidate, SCI-110, in children with Autism Spectrum Disorder.
Which regulatory body granted the renewal of approval for SciSparc's trial?
The Israeli Medical Cannabis Agency granted the renewal of approval.
What is the name of SciSparc's drug candidate being tested?
SciSparc's drug candidate being tested is named SCI-110.
On what date was the announcement of the trial renewal made?
The announcement was made on December 31, 2024.
What condition is SciSparc's clinical trial focused on treating?
SciSparc's clinical trial is focused on treating Autism Spectrum Disorder.
Filing Stats: 322 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-12-31 16:01:01
Filing Documents
- ea0226402-6k_scisparc.htm (6-K) — 12KB
- ea022640202ex99-1_scisparc.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-113959.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: December 31, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3